Compare Unilever plc (UL) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Unilever plc vs State Street SPDR S&P Biotech ETF — how do they compare? Unilever plc trades at $62.18 (market cap $131.86B), while State Street SPDR S&P Biotech ETF trades at $154.41. The key difference: Unilever plc pays a 3.68% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Unilever plc nearer its low. Which is the better fit depends on your goals.
| UL | XBI | |
|---|---|---|
Market Cap | $131.86B | — |
Sector | Consumer Staples | Broad Market / Factor |
52-Week High | $74.59 | $164.28 |
52-Week Low | $55.05 | $85.16 |
Enterprise Value | $157.31B | — |
Dividend Yield | 3.68% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Unilever (UL) trades at $60.79, down 2.56% today, with a mixed technical and fundamental backdrop. The stock shows a bullish technical signal from moving averages but has missed earnings expectations in recent quarters. Revenue in 2024 was $60.76B with a net income margin of 9.45%, while the company explores strategic moves like a potential bid for Thorne and a partnership with Accenture to scale AI in manufacturing.
The outlook is balanced; strong cash flow and a high ROE of 53.32% support the dividend, but recent earnings misses and a high P/B ratio of 7.55 pose risks. Analyst sentiment is neutral with a 51.36% hold rating, reflecting cautious optimism amid execution challenges and macroeconomic headwinds.
XBI trades at $150.94, down 2.14% today, with technical indicators showing a bearish trend but oversold RSI suggesting potential near-term support. The ETF lacks traditional valuation metrics due to its structure, but recent news highlights strong biotech sector momentum, including a 17% monthly gain and robust M&A activity. Analyst coverage is limited to a single hold rating, reflecting cautious optimism amid sector volatility.
Outlook: Biotech sector tailwinds from M&A and AI-driven drug discovery offer upside, but high volatility and policy risks persist. Investors should weigh XBI's equal-weight exposure to small/mid-cap biotech against its elevated beta, with technical support near $149 critical for short-term direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Unilever plc
Unilever is a diversified personal product (42% of 2021 sales by value), home care (20%), and packaged food (38%) company. Its brands include Knorr soups and sauces, Hellmann's mayonnaise, Lipton teas, Axe and Dove skin products, and the TRESemme haircare brand. The firm has been acquisitive in recent years
Read more on UL →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
